Arcutis Biotherapeutics
ARQT
ARQT
228 hedge funds and large institutions have $1.78B invested in Arcutis Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 90 increasing their positions, 65 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
9% less capital invested
Capital invested by funds: $1.95B → $1.78B (-$173M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
22% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 45
Holders
228
Holding in Top 10
5
Calls
$10.3M
Puts
$3.24M
Top Buyers
| 1 | +$31M | |
| 2 | +$15.3M | |
| 3 | +$12.9M | |
| 4 |
Goldman Sachs
New York
|
+$11M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$9.64M |
Top Sellers
| 1 | -$23.8M | |
| 2 | -$22.9M | |
| 3 | -$17.2M | |
| 4 |
CM
Cercano Management
Bellevue,
Washington
|
-$14.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.69M |
